Moleculin Biotech (MBRX) Corporate Connect Webinar Series summary

Management and strategic direction

• Leadership team has over 200 years of drug development experience, with 7 FDA approvals and 2 Big Pharma exits.

• Recently added an ex-Roche executive as a strategic advisor to support outlicensing and partnering, expecting such transactions within 12 months.

• Management invested $1 million after-tax in company stock, signaling confidence.

Pipeline and technology focus

• Portfolio includes three technologies discovered at MD Anderson Cancer Center, all with Phase 2 human activity.

• Current resources are focused on Annamycin, nearing a Phase 3 data inflection point.

• Other technologies progress via NIH and grant funding, mainly through investigator-initiated trials.

Annamycin: clinical and market potential

• Annamycin is a next-generation anthracycline designed to be non-cardiotoxic, with no evidence of heart damage in over 100 patients, even at high doses.

• Avoids cross-resistance with existing anthracyclines and standard-of-care treatments, enabling higher dosing and potential use as maintenance therapy.

• Holds patent protection through 2040, with recent additional patents, orphan drug, and fast-track status.